Development and Validation of Machine Learning Models: Electronic Health Record Data To Predict Visual Acuity After Cataract Surgery.
Journal
The Permanente journal
ISSN: 1552-5775
Titre abrégé: Perm J
Pays: United States
ID NLM: 9800474
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
To develop predictive models of final corrected distance visual acuity (CDVA) following cataract surgery using machine learning algorithms and electronic health record data. In this predictive modeling study we used decision tree, random forest, and gradient boosting. We included the first surgical eye of 64,768 members of Kaiser Permanente Northern California who underwent cataract surgery from June 1, 2010 through May 31, 2015. We measured discrimination and calibration of machine learning models for predicting postoperative CDVA 20/50 or worse vs 20/40 or better. The training set included 51,712 patients, and the validation set included 13,056 patients. We compared 3 machine learning models and found that the gradient boosting model provided the best discrimination ability for CDVA. The most important variables for predicting final CDVA 20/50 or worse were preoperative CDVA, age, and age-related macular degeneration, which together accounted for 41% of the gain in optimization of the gradient boosting model. Other important variables in the model included dispensed glaucoma medication, epiretinal membrane, cornea disorder, cataract surgery operating time, surgeon experience, and census block neighborhood characteristics (household income, family income, family poverty, college education, and home residence by owner). For predicting CDVA after cataract surgery, gradient boosting had the best ability to discriminate patients with postoperative CDVA 20/50 or worse from patients with postoperative CDVA 20/40 or better. Machine learning has the potential to improve prognosis and can improve patient information when making decisions to undergo cataract surgery.
Sections du résumé
BACKGROUND
To develop predictive models of final corrected distance visual acuity (CDVA) following cataract surgery using machine learning algorithms and electronic health record data.
METHODS
In this predictive modeling study we used decision tree, random forest, and gradient boosting. We included the first surgical eye of 64,768 members of Kaiser Permanente Northern California who underwent cataract surgery from June 1, 2010 through May 31, 2015. We measured discrimination and calibration of machine learning models for predicting postoperative CDVA 20/50 or worse vs 20/40 or better.
RESULTS
The training set included 51,712 patients, and the validation set included 13,056 patients. We compared 3 machine learning models and found that the gradient boosting model provided the best discrimination ability for CDVA. The most important variables for predicting final CDVA 20/50 or worse were preoperative CDVA, age, and age-related macular degeneration, which together accounted for 41% of the gain in optimization of the gradient boosting model. Other important variables in the model included dispensed glaucoma medication, epiretinal membrane, cornea disorder, cataract surgery operating time, surgeon experience, and census block neighborhood characteristics (household income, family income, family poverty, college education, and home residence by owner).
CONCLUSION
For predicting CDVA after cataract surgery, gradient boosting had the best ability to discriminate patients with postoperative CDVA 20/50 or worse from patients with postoperative CDVA 20/40 or better. Machine learning has the potential to improve prognosis and can improve patient information when making decisions to undergo cataract surgery.
Identifiants
pubmed: 33635778
doi: 10.7812/TPP/20.188
pmc: PMC8817938
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Subventions
Organisme : NEI NIH HHS
ID : R01 EY027329
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY022989
Pays : United States
Informations de copyright
Copyright © 2020 The Permanente Press. All rights reserved.
Références
JAMA. 2016 Dec 13;316(22):2402-2410
pubmed: 27898976
Ophthalmology. 2018 Jul;125(7):1028-1036
pubmed: 29454659
J Am Stat Assoc. 2015;110(510):583-598
pubmed: 26236062
Med Care. 2010 Jun;48(6 Suppl):S114-20
pubmed: 20473199
Arch Ophthalmol. 2004 Apr;122(4):477-85
pubmed: 15078664
Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):378-385
pubmed: 28052483
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
Clin Exp Ophthalmol. 2019 Jan;47(1):128-139
pubmed: 30155978
Ann Intern Med. 2015 May 19;162(10):735-6
pubmed: 25984857
Int J Ophthalmol. 2018 Sep 18;11(9):1555-1561
pubmed: 30225234
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195
Br J Ophthalmol. 2019 Feb;103(2):167-175
pubmed: 30361278
JAMA. 2015 Sep 8;314(10):1063-4
pubmed: 26348755
J Cataract Refract Surg. 2019 Apr;45(4):404-413
pubmed: 30638823
Ophthalmology. 2019 Mar;126(3):355-361
pubmed: 30808486
Br J Ophthalmol. 2004 Oct;88(10):1242-6
pubmed: 15377542